leisure time -WSS

leisure time

author：Wikipedia 2025-09-29 20:53:07 - browse：32252

Sen. Ron Wyden, D-Ore., left, and Sen. Mike Crapo, R-Idaho, right, walk on Capitol Hill. -- health policy coverage from STAT — Sen. Ron Wyden, D-Ore., left, and Sen. Mike Crapo, R-Idaho, right, walk on Capitol Hill in 2021. Susan Walsh/AP

WASHINGTON — One of the top health care committees in the Senate is assembling ideas for bipartisan legislation to address drug shortages, three Senate aides and three lobbyists told STAT.

The talks, led by Senate Finance Chair Ron Wyden (D-Ore.) and ranking member Mike Crapo (R-Idaho) are in the early days, but they could move the debate over drug shortage reforms into a new phase. The committee has jurisdiction over Medicare and Medicaid payment policies for hospitals. Other committees that have tried tackling the issue have jurisdiction mostly over the Food and Drug Administration.

The panel is tentatively aiming to hold a hearing on the issue in November, the sources said. The panel has also started accepting input from outside stakeholders, one lobbyist said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

WSS

In early work, researchers turn to CRISPR to treat Alzheimer's

Group opposing PBM reform sets lobbying record

Key House panel plots a new health care package

Experts study whether long Covid risk adds up with each reinfection

Readout LOUD podcast: possible new ALS drug, artificial wombs

Custom gene therapy hints at new path for rare disease treatments

focus

leisure time

focus

At least 13 dead in Texas as scorching temps continue

Biotech stock slump in 2023: awaiting the turnaround

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

In early work, researchers turn to CRISPR to treat Alzheimer's

Psychedelics group wrestles with new pharma identity

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Medicare details structure of new drug price negotiation program

How AI helped researchers track recovery from depression

How to save PrEP access — and even expand it

At Orexo, a ‘turning point’ for everything but digital health

focus

Readout LOUD podcast: possible new ALS drug, artificial wombs

STAT Virtual Event: The State of Biosimilars: What to Watch

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

CDC advisers recommend seasonal use of Pfizer RSV shot

CommonSpirit Health keeps growing, even as it loses money

Senators: Long

hotspot

leisure time

hotspot

focus